Anzeige
Mehr »
Mittwoch, 24.06.2026 - Börsentäglich über 12.000 News
Schuldenfrei, 1,5 Mio. Unzen Gold und Produktion ab 2027: Vor dem Ausbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 907048 | ISIN: FR0000035370 | Ticker-Symbol: 1DJ
Stuttgart
23.06.26 | 21:57
22,450 Euro
-1,32 % -0,300
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BASTIDE LE CONFORT MEDICAL SA Chart 1 Jahr
5-Tage-Chart
BASTIDE LE CONFORT MEDICAL SA 5-Tage-Chart
RealtimeGeldBriefZeit
22,40023,70023.06.
Actusnews Wire
403 Leser
Artikel bewerten:
(2)

BASTIDE: Groupe Bastide sells New Medical Concept, the holding company of EXPERF group

Caissargues, 21 May 2026 -Groupe Bastide today announced the signing of an agreement for the disposal of its subsidiary New Medical Concept, the holding company of the French group EXPERF, specialized in home infusion and clinical nutrition care, to Sapio Group.

Since its acquisition in 2017, EXPERF has delivered sustained growth, with revenue more than doubling over the period, driven by the expansion of its regional footprint and the strengthening of its operational teams. In 2017, EXPERF generated revenue of approximately €18 million and operated more than 15 locations in France. The group now operates a network of 28 agencies and generated revenue of €42 million for the 2024-2025 financial year.

The transaction is fully aligned with Groupe Bastide's disciplined portfolio management and asset rotation strategy. It will enable Groupe Bastide to crystallize the significant value created since the acquisition of EXPERF, following a strong growth trajectory, while further strengthening Groupe Bastide's financial structure. This all-cash transaction will support continued deleveraging, reduce financial expenses, and improve the financial leverage ratio (post-IFRS 16), which is expected to stand slightly above 2.5x post-transaction, compared with 2.77x as of December 31, 2025.

Given the expected timing of deconsolidation, this disposal will not have a material impact on reported revenue for the current financial year (ending June 30, 2026). Groupe Bastide confirms its full-year guidance of at least €510 million in revenue, with an operating margin of around 9.0%.

Oddo BHF acted as Exclusive Financial Advisor to Groupe Bastide and ADVANT Altana as legal advisor.

Sapio Group was supported by Goodwin Procter LLP as legal advisor and Eight Advisory as financial and tax advisors. Marsh supported the insurance due diligence.

Completion of the transaction is subject to customary closing conditions, including information and consultation with employee representative bodies.

"We are pleased to have signed the agreement to acquire the EXPERF," says Mario Paterlini, CEO of the Sapio Group. "This acquisition marks another important milestone in our strategy which aims at delivering sustainable growth in Europe, particularly in the healthcare sector, which is experiencing strong momentum. With its well-established footprint across France, EXPERF will be a booster to our consolidation strategy and expansion in the country."

"The disposal of EXPERF once again demonstrates our ability to maximize and realize the value of our assets through a disciplined asset rotation strategy," said Vincent Bastide, Chairman and CEO of Groupe Bastide. This transaction is fully in line with our ongoing commitment to deleveraging the Group, while supporting EXPERF in its next phase of development under its new shareholder."

About Groupe Bastide Le Confort Médical

Created in 1977 by Guy Bastide, Groupe Bastide is a leading European provider of home healthcare services. Present in 8 countries, Bastide develops a permanent quality approach and is committed to providing medical devices and associated services that best meet patients' needs in key health areas: diabetes, nutrition, infusion, respiratory care, stomatherapy and urology.

Bastide is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, - Bloomberg BLC: FP).


About Sapio Group

Founded in 1922 in Monza (Italy), Sapio is an Italian multinational controlled 51% by the Dossi and Colombo families and 49% by Air Products and Chemicals (USA). The Group operates in the industrial, medicinal gases and home care sector in Italy, France, UK, Germany, Slovenia, Turkey, Spain, Portugal and the United States with a workforce of approximately 3.000 employee and 200 thousand patients assisted in Europe every year. Sapio, whose turnover will exceed €1 billion once this acquisition is completed, will further expand its activities in France, where it is already operating with Homeperf and Synapse SAS. With this transaction the footprint of Sapio in France will significantly develop to more than €140 million in revenues in the country.

NEXT PUBLICATION:

2025-2026 annual revenue on Thursday, September 3, 2026 after the close of trading


CONTACTS

Groupe BastideActus Finance

Vincent Bastide/Olivier Jourdanney
T. +33 (0)4 66 38 68 08
www.bastide-groupe.fr

Analystes-Investisseurs
Hélène de Watteville
T. +33 (0)1 53 67 36 33

Presse - Médias
Déborah Schwartz
T. +33 (0)1 53 67 36 35

Sapio Group

Luca Primavera
T. +39 3357247417
luca.primavera@sapio.it
www.grupposapio.it
------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yGlsYJqYkmnFnnCbapyYmGpjbZxqlZWaa2Wex5NwaJqanGlll2eWapSWZnJpmGxo
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-98372-experf-veng-vdef.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2026 Actusnews Wire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.